Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ: SILO )

0.8900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102,853
Open 0.9200
Bid (Size) 0.8900 (109)
Ask (Size) 0.9007 (20)
Prev. Close 0.8900
Today's Range 0.8801 - 0.9302
52wk Range 0.7700 - 4.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Ketamine Implant Development with Pharmacokinetic Study
Via Investor Brand Network

Performance

YTD
-41.45%
-41.45%
1 Month
-15.24%
-15.24%
3 Month
-19.09%
-19.09%
6 Month
-9.55%
-9.55%
1 Year
-41.45%
-41.45%

More News

Read More
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partners with Kymanox to Advance Ketamine Implant Therapeutic for Chronic Pain
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Is Silo Pharma Stock Gaining Today?
Via Benzinga
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Promising Preclinical Results for SPC-15 in Treating Severe Psychiatric Disorders
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Promising Results from Testing of Ketamine-Loaded Implant for Chronic Pain Relief
Via Investor Brand Network
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports on FDA Pre-IND Meeting to Advance Development of Lead Program
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO), Sever Pharma Expand Existing Agreement to Include Extrusion of Novel Ketamine Implant Therapeutic
Via Investor Brand Network
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Agreement to Launch New Study of SPU-16 Homing Peptide for Multiple Sclerosis
Via Investor Brand Network
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) to Participate in Upcoming H.C. Wainwright Annual Global Investment Conference
Via Investor Brand Network
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Crude Oil Down 3%; Netflix Earnings Top Estimates
Via Benzinga
Exposures Fossil Fuels
Why Selective Insurance Group Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters into $2.1M Registered Direct Offering
Via Investor Brand Network
Gold Down 2%; SLB Posts Upbeat Earnings
Via Benzinga
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.